Javier R Lama1, Rachel A Bender Ignacio2,3, Ricardo Alfaro4, Jessica Rios1, Jorge Gallardo Cartagena4, Rogelio Valdez3,5, Carolyn Bain6, Karin Sosa Barbarán4, Manuel V Villaran1,7, Christopher D Pilcher8, Pedro Gonzales1, Jorge Sanchez1,4, Ann Duerr2,3. 1. Asociacion Civil Impacta Salud y Educacion, Lima, Perú. 2. University of Washington, Seattle, Washington, USA. 3. Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Centro de Investigaciones Tecnologicas, Biomedicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Perú. 5. Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 6. Program for the Appropriate Use of Technology in Health, Seattle, Washington, USA. 7. Auna, Lima, Perú. 8. Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, California, USA.
Abstract
BACKGROUND: In addition to demonstrated public health benefits on reducing transmission, it remains unclear how early antiretroviral therapy (ART) must be started after acquisition of human immunodeficiency virus (HIV) to maximize individual benefits. METHODS: We conducted an open-label randomized clinical study in Lima, Peru among adult men who have sex with men and transgender women with acute (HIV-antibody negative/HIV-1 RNA positive) or recent (confirmed negative HIV-antibody or RNA test within 3 months) HIV infection, who were randomized to start ART immediately versus defer by 24 weeks. We evaluated outcomes by treatment arm and immunologic markers by days since estimated date of detectible infection (EDDI). RESULTS:Of 216 participants, 105 were assigned to immediate arm and 111 to deferred arm (median age 26.8 years, 37% with acute HIV). The incidence of non-ART-related adverse events was lower in immediate versus deferred arm (83 vs 123/100 person-years, IRR 0.67 (95% confidence interval [CI] .47, .95; P = .02), the difference dominated by fewer infections in those treated immediately. After 24 weeks of ART, between-group differences in CD4/CD8 cell ratio lessened (P = .09 overall), but differences between those initiating ART ≤ 30 days from EDDI (median 1.03, interquartile range [IQR] 0.84, 1.37), and those initiating > 90 days (0.88, IQR 0.61, 1.11) remained, P = .02. Principal components analysis of 20 immune biomarkers demonstrated distinct patterns between those starting ART > 90 days from EDDI versus those starting within 30 or 90 days (both P < .001). CONCLUSIONS: To our knowledge, this is the only evaluation of randomized ART initiation during primary HIV and provides evidence to explicitly consider acute HIV in World Health Organization recommendations for universal ART. CLINICAL TRIALS REGISTRATION: NCT01815580.
RCT Entities:
BACKGROUND: In addition to demonstrated public health benefits on reducing transmission, it remains unclear how early antiretroviral therapy (ART) must be started after acquisition of human immunodeficiency virus (HIV) to maximize individual benefits. METHODS: We conducted an open-label randomized clinical study in Lima, Peru among adult men who have sex with men and transgender women with acute (HIV-antibody negative/HIV-1 RNA positive) or recent (confirmed negative HIV-antibody or RNA test within 3 months) HIV infection, who were randomized to start ART immediately versus defer by 24 weeks. We evaluated outcomes by treatment arm and immunologic markers by days since estimated date of detectible infection (EDDI). RESULTS: Of 216 participants, 105 were assigned to immediate arm and 111 to deferred arm (median age 26.8 years, 37% with acute HIV). The incidence of non-ART-related adverse events was lower in immediate versus deferred arm (83 vs 123/100 person-years, IRR 0.67 (95% confidence interval [CI] .47, .95; P = .02), the difference dominated by fewer infections in those treated immediately. After 24 weeks of ART, between-group differences in CD4/CD8 cell ratio lessened (P = .09 overall), but differences between those initiating ART ≤ 30 days from EDDI (median 1.03, interquartile range [IQR] 0.84, 1.37), and those initiating > 90 days (0.88, IQR 0.61, 1.11) remained, P = .02. Principal components analysis of 20 immune biomarkers demonstrated distinct patterns between those starting ART > 90 days from EDDI versus those starting within 30 or 90 days (both P < .001). CONCLUSIONS: To our knowledge, this is the only evaluation of randomized ART initiation during primary HIV and provides evidence to explicitly consider acute HIV in World Health Organization recommendations for universal ART. CLINICAL TRIALS REGISTRATION: NCT01815580.
Authors: Irini Sereti; Shelly J Krebs; Nittaya Phanuphak; James L Fletcher; Bonnie Slike; Suteeraporn Pinyakorn; Robert J O'Connell; Adam Rupert; Nicolas Chomont; Victor Valcour; Jerome H Kim; Merlin L Robb; Nelson L Michael; Daniel C Douek; Jintanat Ananworanich; Netanya S Utay Journal: Clin Infect Dis Date: 2016-10-12 Impact factor: 9.079
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Javier R Lama; Audrey Brezak; James G Dobbins; Hugo Sanchez; Robinson Cabello; Jessica Rios; Carolyn Bain; Angela Ulrich; Robert De la Grecca; Jorge Sanchez; Ann Duerr Journal: Am J Epidemiol Date: 2018-08-01 Impact factor: 4.897
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja Journal: N Engl J Med Date: 2013-01-17 Impact factor: 91.245
Authors: Michael J Vinikoor; Anna Cope; Cynthia L Gay; Guido Ferrari; Kara S McGee; Joann D Kuruc; Jeffrey L Lennox; David M Margolis; Charles B Hicks; Joseph J Eron Journal: J Acquir Immune Defic Syndr Date: 2013-04-15 Impact factor: 3.731
Authors: Katherine Garcia-Rosales; Karin Sosa Barbaran; Jessica Rios; Delia Pinto-Santini; Maria Del Rosario Leon; Jorge A Gallardo-Cartagena; John MacRae; Mey Leon; Javier Valencia-Huamaní; Esmelda Montalban; Pedro Gonzales; Ann Duerr; Javier R Lama; Rachel Bender Ignacio Journal: AIDS Patient Care STDS Date: 2022-06 Impact factor: 5.944
Authors: Trupti Gilada; Samuel R Schnittman; Edward White; Jacqueline Mercader; Yixin Wang; Sayan Dasgupta; Rogelio Valdez; Delia Pinto-Santini; Siavash Pasalar; Jorge Sanchez; Pedro Gonzales; Javier R Lama; Rachel Bender Ignacio; Ann Duerr Journal: Open Forum Infect Dis Date: 2022-03-24 Impact factor: 4.423
Authors: Jack A Collora; Runxia Liu; Delia Pinto-Santini; Neal Ravindra; Carmela Ganoza; Javier R Lama; Ricardo Alfaro; Jennifer Chiarella; Serena Spudich; Karam Mounzer; Pablo Tebas; Luis J Montaner; David van Dijk; Ann Duerr; Ya-Chi Ho Journal: Immunity Date: 2022-03-22 Impact factor: 43.474